FDA Faces 5% Staff Cutbacks In 1995

9 October 1994

The US Food and Drug Administration's total budget for salaries and expenses in fiscal 1995 will be $905.9 million, the Senate has agreed, in its vote on the House/Senate conference report on next year's agriculture spending bill (HR 4554).

The earlier House vote on the report had agreed on a budget for the agency of $899.4 million, but this did not include an additional $6.5 million represented by mammography inspection fees.

Senator Dale Bumpers, chairman of the appropriations/agriculture subcommittee, says the agreed budget for next year will be $36.3 million higher than fiscal 1994's. The House had initially proposed a total for the agency of $914.4 million, while the original plan from the Senate had been $754.6 million, on top of which the upper house had included a proposal for raising $163.4 million in user fees for unspecified, FDA-regulated products. However, in August the House overturned this proposal, under a Ways and Means Committee resolution, on the grounds that it violated the constitutional requirement that all measures adopted as a way of creating revenue should originate in the House.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight